Dendreon's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Dendreon (DNDN) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Dendreon vs Its Competitors
- TTM: Trailing 12-month revenue of 299M vs -M combined for tracked competitors (100.0% combined share).
- Trending: Latest-quarter revenue run-rate is decelerating (-2.2% annualized vs trailing 12 months).
- Peer revenue share: Dendreon accounted for 100.0% of combined revenue among its tracked peer group, up from 100.0% a year earlier.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
DNDN Sales vs. its Competitors, 2014
Dendreon generated 100.00 % of the combined sales of its peer group, up from 100.00 % a year earlier.
For context: the Biotechnology & Pharmaceuticals industry grew revenue 21.1% year over year, combined, vs 7.5% for Dendreon. Dendreon's share of combined industry revenue moved from 0.19% to 0.17%, a loss of 0.02 percentage points.
Dendreon's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Dendreon Corp | No | Yes | No | No |
| Similar Growth & Profitability (8) | 14.30 % (1 of 7) | 62.50 % (5 of 8) | 50.00 % (4 of 8) | 25.00 % (2 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.